None listed
Conditions
Interventions
None listed
Sponsors
Chonnam National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We enroll all patients fulfilled four or more of the American College of Rheumatology (ACR) 1997 revised classification criteria for SLE. * The revised criteria for the diagnosis of systemic lupus erythematosus 1. Malar rash: Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds 2. Discoid rash: Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions 3. Photosensitivity: Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation 4. Oral ulcers: Oral or nasopharyngeal ulceration, usually painless, observed by physician 5. Arthritis: Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion 6. Serositis a) Pleuritis: convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion OR b) Pericarditis: documented by ECG or rub or evidence of pericardial effusion 7. Renal disorder a) Persistent proteinuria > 500 mg per day or > 3 + if quantitation not performed OR b) Cellular casts: may be red cell, haemoglobin, granular, tubular, or mixed 8. Neurologic disorder a) Seizures: in the absence of offending drugs or known meta-bolic derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance OR b) Psychosis: in the absence of offending drugs or known metabolic derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance 9. Hematologic disorder a) Hemolytic anemia-with reticulocytosis OR b) Leukopenia: < 4,000/mm3 total OR c) Lymphopenia: < 1,500/mm3 on two or more occasions OR d) Thrombocytopenia: < 100,000/mm3 in the absence of offending drugs 10. Immunologic disorder a) Anti-DNA: antibody to native DNA in abnormal titre OR b) Anti- Sm: presence of antibody to Sm nuclear antigen OR c) Positive finding of antiphospholipid antibodies based on (1) an abnormal serum level of lgG or lgM anticardiolipin antibodies, (2) a positive test result for lupus anticoagulant using a standard method, or (3) a false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test 11. ANA: Abnormal titer of ANA by immunofluorescence or equivalent assay at any point in time, in the absence of drugs known to be associated with drug-induced lupus syndrome This classification is based on 11 criteria. For the purpose of identifying patients in clinical studies, a person must have SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any lnterval of observation.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had incomplete data or advanced co-morbidity, such as diabetus or primary kidney disease that could affect complicate assessment of lupus activity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prognosis, cor-morbidity and treatment efficacy of SLE | — |
Secondary
| Measure | Time frame |
|---|---|
| prevalence and prognosis of lupus nephritis | — |
Countries
Korea, Republic of
Contacts
Public ContactDong-Jin Park
Chonnam National University Hospital
Outcome results
None listed